Silva LC, Pérez-de-Oliveira ME, Pedroso CM, Leite AA, Santos-Silva AR, Lopes MA, et al. Systemic therapies for salivary gland carcinomas: an overview of published clinical trials. Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29 (2):e280-7.
doi:10.4317/medoral.26264
https://dx.doi.org/doi:10.4317/medoral.26264
1. Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, et al. Systemic therapy for salivary gland malignancy: current status and future perspectives. Jpn J Clin Oncol. 2022;52:293-302. |
PMid:35134985 |
2. Zang S, Chen M, Huang H, Zhu X, Li X, Yan D, et al. Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study. Quant Imaging Med Surg. 2022;12:2841-54. |
PMid:35502385 PMCid:PMC9014160 |
3. Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, et al. Management of Salivary Gland Malignancy: ASCO Guideline. Journal of Clinical Oncology. 2021;39:1909-41. |
PMid:33900808 |
4. Coca-Pelaz A, Rodrigo JP, Triantafyllou A, Hunt JL, Rinaldo A, Strojan P, et al. Salivary mucoepidermoid carcinoma revisited. European Archives of Oto-Rhino-Laryngology. 2015;272:799-819. |
PMid:24771140 |
5. Lopes MA, Da Cruz Perez DE, De Abreu Alves F, De Almeida OP, Kowalski LP. Clinicopathologic and immunohistochemical study of intraoral mucoepidermoid carcinoma. Otolaryngology - Head and Neck Surgery. 2006;134:622-6. |
PMid:16564385 |
6. Louredo BVR, Santos-Silva AR, Vargas PA, Ajudarte Lopes M, Martins MD, Guerra EN da S, et al. Clinicopathological analysis and survival outcomes of primary salivary gland tumors in pediatric patients: A systematic review. Journal of Oral Pathology and Medicine. 2021;50:435-43. |
PMid:33314344 |
7. Noguchi K, Kanda S, Yoshida K, Funaoka Y, Yamanegi K, Yoshikawa K, et al. Establishment of a patient-derived mucoepidermoid carcinoma cell line with the CRTC1-MAML2 fusion gene. Mol Clin Oncol. 2022;16:1-12. |
PMid:35251626 PMCid:PMC8848773 |
8. Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021;11:4092-110. |
PMid:34659878 |
9. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91:541-7. |
https://doi.org/10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y |
PMid:11169936 |
10. Airoldi M, Garzaro M, Pedani F, Ostellino O, Succo G, Riva G, et al. Cisplatin + vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): A final report on 60 cases. American Journal of Clinical Oncology: Cancer Clinical Trials. 2017;40:86-90. |
PMid:25089531 |
11. Licitra L, Marchini S, Spinazzè S, Rossi A, Rocca A, Grandi C, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991;68:1874-7. |
https://doi.org/10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S |
PMid:1913539 |
12. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 2009;45:574-8. |
PMid:18804410 |
13. Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G, et al. Abiraterone Acetate in Patients with Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. Journal of Clinical Oncology. 2021;39:4061-8. |
PMid:34597119 PMCid:PMC8677956 |
14. Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011;117:3374-82. |
PMid:21246525 PMCid:PMC3135694 |
15. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, et al. Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group. Head Neck. 2006;28:197-204. |
PMid:16470745 |
16. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724-7. |
PMid:12907212 |
17. Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, et al. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020;126:3972-81. |
PMid:32557577 PMCid:PMC8266417 |
18. Rodriguez CP, Wu Q, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clinical Cancer Research. 2020;26:837-45. |
PMid:31796519 |
19. Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, et al. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40:55-62. |
PMid:29044862 |
20. Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer. 2017;123:1958-64. |
PMid:28102887 |
21. Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979-84. |
PMid:29211833 PMCid:PMC5913639 |
22. Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC. Annals of Oncology. Elsevier Masson SAS. 2012;23:1562-70. |
PMid:22080184 |
23. Jones AS, Phillips DE, Cook JA, Helliwell TR. A randomised phase ii trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer. 1993;67:112-4. |
PMid:7678976 PMCid:PMC1968228 |
24. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines ® insights: Head and neck cancers, version 1.2018 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 2018;16:479-90. |
PMid:29752322 |
25. Guimarães DM, Almeida LO, Martins MD, Warner KA, Silva ARS, Vargas PA, et al. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget. 2016;7:42447-60. |
PMid:27285758 PMCid:PMC5173147 |
26. Silva LC, Borgato GB, Wagner VP, Martins MD, Rocha GZ, Lopes MA, et al. Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells. Journal of Oral Pathology and Medicine. 2022;51:553-62. |
PMid:34661317 PMCid:PMC9013730 |
27. Wagner VP, Martins MAT, Martins MD, Warner KA, Webber LP, Squarize CH, et al. Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axis. Oncotarget. 2016;7:73032-44. |
PMid:27682876 PMCid:PMC5341961 |
28. Wagner VP, Martins MD, Martins MAT, Almeida LO, Warner KA, Nör JE, et al. Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep. 2018;8:1-11. |
PMid:29391537 PMCid:PMC5794736 |
29. Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget. 2017;8:32918-29. |
PMid:28415633 PMCid:PMC5464838 |
30. Mueller SK, Haderlein M, Lettmaier S, Agaimy A, Haller F, Hecht M, et al. Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer. J Clin Med. 2022;11:720. |
PMid:35160172 PMCid:PMC8836387 |
31. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine. 2018;378:731-9. |
PMid:29466156 PMCid:PMC5857389 |
32. Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, et al. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist. 2022. |
PMid:35536733 |
33. Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, et al. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? Oral Oncol. 2017;66:58-63. |
PMid:28249649 |
34. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, et al. Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study. Journal of Clinical Oncology. 2005;23:585-90. |
PMid:15659505 |
35. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43:33-6. |
PMid:16757202 |